Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung condition characterized by persistent, often progressive airflow obstruction. It results from abnormalities of the airways, including bronchitis and bronchiolitis, and/or the alveoli, as seen in emphysema. Common symptoms include dyspnea, cough, sputum production, activity limitation, and acute exacerbations that can significantly impair health status.
COPD develops through interactions between genetic susceptibility and environmental exposures throughout life. Tobacco smoking remains a major risk factor, but household and outdoor air pollution, occupational exposure to dust and chemical agents, abnormal lung development, and accelerated lung aging also contribute. Recognizing these diverse causes is essential for prevention, diagnosis, and long-term management.
By América Torres
The Global Burden of COPD
COPD is a leading cause of morbidity and mortality worldwide. Its prevalence and impact vary across countries because of differences in population age structure, environmental exposures, smoking patterns, socioeconomic conditions, and access to healthcare.
COPD Prevalence Worldwide
According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 20264 Report, estimates of COPD prevalence vary considerably according to diagnostic criteria, survey methods, study populations, and analytical approaches.
The Global Burden of Disease (GBD) 2021 analysis estimated 213.39 million prevalent COPD cases worldwide in 20219. In contrast, Adeloye et al.1, in a systematic review and modeling study of population-based spirometric surveys, estimated a global prevalence of 391.9 million cases among adults aged 30–79 years in 2019. Of these, approximately 315.5 million cases, or 80.5%, occurred in low- and middle-income countries (LMICs)1. These estimates should not be interpreted as directly interchangeable. The GBD estimate includes all ages and uses a different modeling framework. Whereas the 391.9-million estimate is restricted to adults aged 30–79 years and bases on population studies using spirometry. Nevertheless, both estimates demonstrate the substantial worldwide impact of COPD.
The burden will continue to increase. Boers et al.2, in a global modeling study, projected a 23% increase in COPD cases between 2020 and 2050, approaching 600 million cases among people aged 25 years or older by 2050. The projected increase was greater among women and in LMICs2 . This figure is a model-based projection rather than an observed epidemiological count and should be reported together with its modeled population and time horizon.
COPD Prevalence Across the 11 Highest-Ranking U.S. States
In the United States, COPD prevalence also varies substantially by state. State surveillance estimates are generally based on self-reported physician-diagnosed COPD and therefore should not be presented as spirometry-confirmed prevalence. In 2021, age-standardized self-reported COPD prevalence ranged from 3.0% in Hawaii to 11.8% in West Virginia5 . Earlier state-level surveillance also identified Appalachian and southeastern states, including West Virginia and Kentucky, among those with a high COPD burden7. Reported percentages and rankings vary by year, survey methodology, age standardization, and case definition; the year and definition should therefore accompany every state-specific estimate.
To illustrate the urgency of early COPD assessment, the following table highlights the 11 U.S. states with the highest reported COPD prevalence, based on state-level estimates.
Pulmonary Function Testing in COPD Diagnosis and Monitoring
Accurate diagnosis is fundamental to reducing the burden of COPD. However, underdiagnosis remains widespread, limiting opportunities for appropriate risk-factor modification, treatment, and disease management.
Spirometry as the Diagnostic Standard
Spirometry is essential for confirming COPD. In a patient with compatible respiratory symptoms and relevant exposure history, a post-bronchodilator forced expiratory volume in 1 second/forced vital capacity ratio (FEV₁/FVC) below 0.70 confirms persistent airflow obstruction and supports the diagnosis of COPD6 . Symptoms alone cannot establish a COPD diagnosis. Clinicians should evaluate patients who experience:
- Dyspnea
- Cough
- Sputum production
- Wheezing
- Activity limitation
The need for evaluation is particularly important in individuals with:
- Tobacco exposure
- Occupational exposure
- Household air-pollution exposure
- Ambient air-pollution exposure
Clinicians should interpret the fixed ratio in the clinical context, particularly in older adults, because it may identify obstruction in some individuals whose values remain above the lower limit of normal. Conversely, post-bronchodilator testing is important because pre-bronchodilator measurements can overestimate obstruction and may miss some patients whose obstruction becomes apparent after bronchodilation6.
The GOLD 2026 Report highlights the extent of underdiagnosis. Lamprecht et al. analyzed 30,874 adults from 44 sites in 27 countries and found that 81.4% of spirometrically defined COPD cases were undiagnosed. The study used post-bronchodilator FEV₁/FVC below the lower limit of normal rather than exclusively the fixed 0.70 ratio. And the results, therefore, should not be generalized without noting the diagnostic definition and study population. These findings support greater access to diagnostic spirometry and structured case finding in people with respiratory symptoms or clinically relevant exposures
Lung Function Assessment Beyond Initial Diagnosis
Pulmonary function testing can provide objective information about respiratory impairment. Reduced FEV₁, gas trapping, hyperinflation, reduced diffusing capacity, and an accelerated decline in FEV₁ may occur in individuals who do not yet meet the spirometric criteria for COPD.
The GOLD Report uses the term pre-COPD for individuals with structural lung abnormalities and/or physiological abnormalities suggestive of early disease despite the absence of persistent airflow obstruction. Preserved Ratio Impaired Spirometry (PRISm) describes abnormal spirometry with a preserved FEV₁/FVC ratio. These categories overlap conceptually but are not synonymous.
Not every individual with pre-COPD or PRISm will develop persistent airflow obstruction. Identifying these patterns may justify further clinical assessment and follow-up. Especially when symptoms or significant exposures are present. However, the presence of pre-COPD or PRISm should not be presented as proof that pharmacological treatment prevents progression. Outside risk-factor modification—particularly smoking cessation—the optimal treatment strategy remains uncertain.
Serial spirometry may help characterize lung-function trajectories over time. This is relevant because COPD may develop through accelerated decline in FEV₁. Or through impaired lung growth and development followed by a relatively normal rate of decline.
The Economic Burden of COPD
COPD imposes substantial direct and indirect costs on healthcare systems, patients, and families. Its economic impact generally increases as disease severity progresses and hospitalization, oxygen therapy, rehabilitation, and caregiver support become more necessary.
According to the GOLD 2026 Report, COPD accounted for an estimated 56% of respiratory disease costs in the European Union, equivalent to €38.6 billion. In the United States, projected COPD-attributable costs over a 20-year period were approximately $800.90 billion, or about $40 billion annually. These figures are estimates from specific economic models and should be accompanied by the study year, perspective, and cost components used.
More recent global projections estimated that cumulative direct COPD costs could reach $24.35 trillion. And cumulative indirect costs $15.43 trillion between 2025 and 20504. These are cumulative modeled costs, not annual global expenditures.
Exacerbations account for a substantial proportion of COPD-related healthcare use. As disease severity increases, hospitalization and ambulatory oxygen costs can rise considerably. Direct medical costs do not reflect the full societal cost of home-based care. They exclude unpaid care provided by family members.
In LMICs, limited access to affordable inhaled medications and diagnostic spirometry creates additional challenges. Severe disability may force both patients and family caregivers to leave the workforce, increasing indirect costs and reducing household income.
The Social Burden of COPD
The impact of COPD extends beyond mortality and healthcare expenditure. Breathlessness, fatigue, reduced exercise capacity, and activity limitation can impair daily functioning and independence, while exacerbations may lead to emergency visits, hospitalization, and further functional decline.
The GOLD Report uses disability-adjusted life years (DALYs) to quantify the combined impact of premature mortality and years lived with disability. In 2021, COPD accounted for an estimated 79.8 million DALYs worldwide according to the GBD 2021 (Global Burden of Disease Study 2021) analysis9.
The burden is particularly significant in LMICs, where access to diagnosis, treatment, pulmonary rehabilitation, oxygen therapy, and long-term supportive care may be limited. These disparities reinforce the need for prevention strategies that address both clinical risk factors and barriers to healthcare access.
COPD Prevention and Early Detection
Reducing the burden of COPD requires earlier recognition of risk, prevention of harmful exposures, and timely diagnostic evaluation. Although tobacco control remains essential, prevention strategies must also address occupational hazards, household air pollution, and ambient air pollution.
Prioritize Targeted Lung Function Testing
Healthcare professionals should maintain a high index of suspicion for COPD in individuals with persistent respiratory symptoms and relevant exposure histories. Particular attention should be given to workers exposed to organic or inorganic dusts, chemical agents, fumes, and pesticides.
Occupational exposure is an underrecognized COPD risk factor. The GOLD Report cites estimates that workplace exposures accounted for approximately 19.2% of COPD cases overall and 31.1% among never-smokers in one United States population-based analysis. These figures represent estimated attributable fractions from a specific study, not the prevalence of COPD among all exposed workers and not a universal estimate for every occupational setting.
Spirometry should be used to confirm suspected COPD. Further testing should be guided by symptoms, exposure history, examination findings, and the initial results. The appropriate strategy is targeted case finding—not routine spirometric screening of asymptomatic adults. The U.S. Preventive Services Task Force recommends against screening asymptomatic adults for COPD using questionnaires or spirometry because evidence has not demonstrated a net benefit8.
Preventive efforts should include tobacco cessation and reducing occupational and environmental exposures. They should also promote clean cooking and heating fuels, vaccination according to current recommendations, and physical activity. Access to pulmonary rehabilitation should be provided when clinically indicated.
Reducing the Burden of COPD Through Earlier Diagnosis
COPD represents a growing clinical, economic, and social challenge. Its substantial prevalence, high rate of underdiagnosis, and increasing costs demonstrate the need for effective prevention and appropriately targeted diagnostic evaluation.
For respiratory healthcare professionals, spirometry remains central to confirming COPD. While broader pulmonary function assessment can characterize respiratory impairment and help identify patients who require further evaluation. Greater attention to occupational exposure and other non-tobacco risk factors is also essential.
Earlier diagnosis should be framed as improved case finding among symptomatic or high-risk individuals, rather than population-wide screening. By integrating exposure assessment, symptom recognition, appropriately indicated pulmonary function testing, smoking cessation, and preventive interventions into respiratory care, healthcare systems can improve opportunities for timely diagnosis and reduce the long-term burden of COPD.
SpiroScout: Reliable Spirometry for Early COPD Detection
Early COPD diagnosis depends on accurate lung function assessment. Spirometry is essential for confirming persistent airflow obstruction, allowing healthcare professionals to identify COPD in patients with compatible clinical findings and risk factors.
The SpiroScout by SCHILLER-GANSHORN is an ultrasonic spirometer designed to support pulmonary function testing with precise, reliable measurements. Its SharpFlow technology measures airflow directly, without requiring calibration or warm-up time. The device is portable, maintenance-free, and easy to clean. Its single-patient-use ScoutTube mouthpieces support hygienic testing, while the LFX software provides clear results and personalized reports. SpiroScout also supports standard spirometry measurements, including forced vital capacity (FVC), slow vital capacity (SVC), and maximum voluntary ventilation (MVV).
These features help respiratory professionals assess lung function efficiently and investigate suspected COPD. Watch the video to see how easy SpiroScout is to use and how ultrasonic spirometry can support pulmonary function testing in clinical practice.
Integrating accurate spirometry into respiratory assessment can help healthcare professionals identify airflow obstruction earlier, confirm suspected COPD, and make timely clinical decisions.
Request a personalized demo of SpiroScout to discover how its ultrasonic spirometry technology can help you identify persistent airflow obstruction and support COPD diagnosis in patients with compatible symptoms and risk factors.
References
Frequently Asked Questions About COPD
What is the global prevalence of chronic obstructive pulmonary disease?
According to the Global Burden of Disease (GBD) 2021 analysis, an estimated 213.39 million prevalent COPD cases occurred worldwide in 2021. This figure represents a modeled estimate of the number of cases, not a single observed prevalence percentage. Estimates vary according to the population studied and the diagnostic criteria used. For example, Adeloye et al. estimated 391.9 million COPD cases among adults aged 30–79 years in 2019 using population-based spirometric data and modeling methods; this estimate is not directly comparable with the GBD 2021 estimate. The global COPD burden is projected to increase in the coming decades, although the magnitude varies according to the assumptions and methods used in each model.
How is COPD diagnosed?
COPD is diagnosed in the appropriate clinical context using post-bronchodilator spirometry. A post-bronchodilator forced expiratory volume in 1 second/forced vital capacity (FEV₁/FVC) ratio below 0.70 confirms persistent airflow obstruction and supports the diagnosis in patients with compatible respiratory symptoms and/or relevant exposure to risk factors. The fixed ratio should be interpreted alongside the patient’s age, symptoms, exposure history, and spirometry quality because it may overestimate obstruction in older adults and underestimate it in younger adults.
Why is early COPD detection important?
Early case finding may identify COPD or related lung-function abnormalities at an earlier stage. This can create an opportunity to address smoking and other harmful exposures, provide evidence-based management, and monitor symptoms, exacerbations, and lung function over time. However, early case finding should not be equated with routine screening of asymptomatic, low-risk adults. The U.S. Preventive Services Task Force recommends against screening asymptomatic adults for COPD; this recommendation does not apply to people with respiratory symptoms or workers with known occupational exposures. Evidence that screening asymptomatic adults improves clinical outcomes remains insufficient.
What role does spirometry play in COPD diagnosis and monitoring?
Spirometry is essential for confirming COPD and provides an objective measurement of airflow obstruction. It can help assess the degree of airflow limitation and evaluate changes in lung function over time. However, clinicians should consider more than spirometry when assessing disease severity, progression, and treatment response. They should also monitor respiratory symptoms, exacerbation history, functional status, exercise capacity, comorbidities, and health-related quality of life.
The SpiroScout by SCHILLER-GANSHORN is an ultrasonic spirometer featuring SharpFlow technology, which measures airflow directly without calibration or warm-up time. It provides key spirometry measurements, including FEV₁, FVC, and SVC, to support pulmonary function assessment and COPD monitoring.
Can occupational exposure increase the risk of COPD?
Yes. Long-term occupational exposure to dust, fumes, gases, chemical agents, and other airborne pollutants can contribute to COPD. Occupational exposures are important risk factors, including among people who have never smoked. The level of risk depends on the type, intensity, and duration of exposure, as well as on coexisting tobacco smoke, biomass smoke, and outdoor air-pollution exposure. Clinicians should therefore ask about patients’ occupational history when evaluating persistent respiratory symptoms.